Business Wire

Galderma Announces Publication of Phase 2b Trial Results Demonstrating the Rapid and Long-lasting Benefits of Nemolizumab in Clinical Trial Subjects With Uncontrolled Atopic Dermatitis

Share

Galderma today announced that the Journal of the European Academy of Dermatology and Venereology (JEADV) has published full results from a post-hoc analysis of the phase 2b study of its investigational therapy, nemolizumab, in adult patients with moderate-to-severe atopic dermatitis (MtS AD).2 Published online on March 12, results of the analyses show that nemolizumab led to rapid and sustained improvements in itch, sleep, and skin lesions in adult patients with uncontrolled MtS AD.2

The published analysis evaluated the efficacy of nemolizumab versus placebo in adult patients with MtS AD:2

  • Nemolizumab-treated patients experienced significant itch relief within 48 hours of treatment (-22.8% vs -12.3%; p=0.005). This improvement was sustained over the trial, achieving even greater treatment benefit at week 16 (-68.5% vs -30.9%; p<0.001 at week 16).
  • Rapid improvement of sleep disturbance for patients treated with nemolizumab (30mg) from day three of treatment (-26.6% vs -9.0%; p<0.001) with further improvement by week 16 of treatment (-76.0% vs -36.5%; p<0.001).
  • Clinically meaningful reductions of 75% EASI were observed at week 16 in 50.0% of nemolizumab patients versus 15.9% of placebo patients (p<0.001) and 90% reductions of EASI were observed for 36.0% of nemolizumab patients and 6.8% of placebo patients (p<0.001).
  • Nemolizumab was safe and well-tolerated in this population, with nasopharyngitis and upper respiratory tract infection being the most common adverse events observed.

“This post-hoc analysis published today in the Journal of the European Academy of Dermatology and Venerology further emphasizes the significant potential of nemolizumab in treating moderate-to-severe atopic dermatitis,” said Dr Baldo Scassellati Sforzolini, Global Head of R&D at Galderma. “In our continued commitment to advancing dermatology, these findings demonstrate the multitude of potential benefits that nemolizumab could bring to people living with this severe and chronic disease.”

 

"Atopic dermatitis is a chronic and debilitating disease. We particularly need more treatment options for patients with moderate-to-severe atopic dermatitis.
Results from these analyses build on our previous knowledge of nemolizumab’s efficacy in atopic dermatitis
and show the potential benefits that it offers for patients with moderate-to-severe atopic dermatitis.”

 

DR JONATHAN SILVERBERG
LEAD AUTHOR, DIRECTOR OF CLINICAL RESEARCH, GEORGE WASHINGTON UNIVERSITY SCHOOL
OF MEDICINE AND HEALTH SCIENCES

 

Analysis methodology
The published post-hoc analysis evaluated the efficacy of nemolizumab versus placebo in adult patients with MtS AD with baseline EASI scores ≥16 (nemolizumab: n=50, placebo: n=44) at week 16. A prior study of nemolizumab has defined MtS AD using an inclusion criteria of EASI ≥12.

About atopic dermatitis
Atopic dermatitis is a disruptive and debilitating inflammatory skin disease, characterized by skin lesions and intense itching, which impacts an estimated 1-3% of adults worldwide.3,4 This severe and chronic skin disease can have a profound impact on patients’ quality of life, leading to sleep difficulties and causing secondary skin infections.5

About nemolizumab
Nemolizumab is a first-in-class humanized monoclonal antibody directed against the IL-31 receptor alpha that blocks signaling from IL-31.6 IL-31 plays a key role in multiple disease mechanisms in both atopic dermatitis and prurigo nodularis, a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated severe pruritus (itching). With its unique role in directly stimulating sensory neurons related to itch and contributing to inflammation and barrier dysfunction, IL-31 is the bridge between the immune and nervous systems while directly acting on structural cells in the skin. Nemolizumab, initially developed by Chugai Pharmaceutical Co., Ltd., was subsequently licensed to Galderma in 2016 – worldwide except Japan and Taiwan. Nemolizumab is an investigational agent under clinical development for the treatment of atopic dermatitis and prurigo nodularis and its safety and efficacy have not been fully evaluated by any regulatory authority. Nemolizumab was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) in December 2019 for the treatment of pruritus associated with prurigo nodularis.

About Galderma
Galderma, the world's largest independent global dermatology company, was created in 1981 and is now present in over 100 countries with an extensive product portfolio of prescription medicines, aesthetics solutions and consumer care products. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit www.galderma.com

1 Atopic Dermatitis. National Eczema Association. Available from: https://nationaleczema.org/eczema/types-of-eczema/atopic-dermatitis/ Accessed: March 2021.
2 Silverberg JI. et al. Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study. JEADV. 2021. DOI: 10.1111/jdv.17218
3 Langan S. et al. Atopic dermatitis. The Lancet. 2020;396(10247):345-360. DOI: https://doi.org/10.1016/S0140-6736(20)31286-1
4 Nutten S. Atopic Dermatitis: Global Epidemiology and Risk Factors. Ann Nutr Metab 2015;66(suppl1):8-16. DOI: https://doi.org/10.1159/000370220
5 Atopic Eczema – Symptoms. NHS. Available from: https://www.nhs.uk/conditions/atopic-eczema/symptoms/ Accessed: March 2021.
6 Saleem M. et al. Interleukin-31 pathway and its role in atopic dermatitis: a systematic review. J Dermatolog Treat. 2017;28(7):591-599. DOI: 10.1080/09546634.2017.1290205

Contact information

Investor and Media Relations
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Media Contact
Lauren Starr
Head of Franchise Communications
media@gladerma.com
+41 79 771 52 45

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Xsolla Introduces Safe and Secure Solution to Manage Worldwide Influencer Payouts for Developers of All Sizes19.4.2021 17:00:00 EEST | Press release

Xsolla, the video game commerce company powered by Transaction Engine and Business Engine to help developers and publishers market, sell, connect and optimize their games globally, today introduced its Influencer Payouts solution that allows developers to easily manage safe and secure payouts to influencers who promote their games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210419005313/en/ Learn how Influencer Payouts can work for you. (Graphic: Business Wire) Xsolla’s new Influencer Payouts solution empowers developers from indie to enterprise-level with a convenient and efficient tool that can automate performance-based payments to content creators utilizing a tiered structure that can quickly be customized and scaled to reach influencers at all levels around the world. Developers can choose from multiple options for influencers, such as revenue sharing based on the number of views, direct sales, or the number of hour

VELO3D Adds Renowned Business Leader Stefan Krause to Board of Directors as Audit Committee Chair19.4.2021 16:04:00 EEST | Press release

VELO3D Inc., a leader in additive manufacturing (AM) for high-value metal parts, today announced the appointment of renowned business leader Stefan Krause to the company’s board of directors as audit committee chair. With more than 30 years of experience working at some of the most recognizable and successful companies in the world, Krause has built a singular career that previously included a chief financial officer (CFO) role at BMW – where he was the youngest ever to hold the position and a member of the management board. Krause then took on a similar role at Deutsche Bank, earning himself a reputation as one of the world’s top CFOs. He also previously served as chairman of Rolls Royce Motorcars, Postbank AG and BHF Bank. He has been in the supervisory boards of Rocket Internet and Allianz AG. Krause has also been involved with multiple startups during his career and has been CEO and co-founder of electric vehicle maker Canoo. “Stefan’s international business background, his experti

Amazon Becomes Europe’s Largest Corporate Buyer of Renewable Energy19.4.2021 16:00:00 EEST | Press release

Amazon (NASDAQ: AMZN) today announced nine new utility-scale wind and solar energy projects in the U.S., Canada, Spain, Sweden, and the UK. The company now has 206 renewable energy projects globally, including 71 utility-scale wind and solar projects and 135 solar rooftops on facilities and stores worldwide, which will generate 8.5 GW of electricity production capacity globally. With this latest announcement, Amazon is now the largest corporate purchaser of renewable energy in Europe, with more than 2.5 GW of renewable energy capacity, enough to power more than two million European homes a year. These projects supply renewable energy to Amazon’s corporate offices, fulfillment centers, Whole Foods Market stores, and Amazon Web Services (AWS) data centers, which power Amazon and millions of AWS customers globally. The renewable energy from these projects also helps Amazon meet its commitment to produce the clean energy equivalent to the electricity used by all consumer Echo devices. All

Schlumberger Will Collaborate With Equinor for DELFI Environment Deployment, Fully Integrated With the OSDU Data Platform19.4.2021 16:00:00 EEST | Press release

Schlumberger and Equinor announced today a strategic project, in collaboration with Microsoft, to deploy the DELFI* cognitive E&P environment, with seamless integration to the OSDU Data Platform—the industry’s new data standard. This project aims to accelerate Equinor’s ability to integrate data at scale and improve decision making. “We are pleased to be working with Equinor and Microsoft to facilitate enhanced resource discovery through this first deployment of the newly-released OSDU Data Platform fully integrated with DELFI,” said Rajeev Sonthalia, president, Digital & Integration, Schlumberger. “This provides a single, unified landscape with seamless access to data that enables the industry to rapidly run AI and data-driven workflows, creating a game-changing increase in efficiency.” The OSDU-enabled solution will be embedded as a key part of Equinor’s Microsoft Azure enterprise-wide data platform, OMNIA. This will establish consistent data standards across the subsurface to enhanc

Gett Strengthens Global Technology Platform to Combine Corporate Fleets and Ride-Hailing19.4.2021 16:00:00 EEST | Press release

Gett, the leading innovator in corporate Ground Transportation Management (GTM), continues to expand its marketplace of global partner fleets onto one technology platform to provide broad geographic coverage and service levels for enterprise clients. Gett launched one of the first-ever on-demand corporate travel services in 2010, attracting Google and Disney among its first clients. With over 10 years of expertise designing seamless ground transportation experiences, Gett reduces corporate spend on ground transportation for its clients by up to 45% by offering price comparison, enforcement of travel policy compliance and optimization of back-office processes. Gett’s platform also provides other benefits, including a seamless rider experience for employers prioritizing the safety and security of their people returning to business travel following Covid-19 lockdown. The expansion of Gett’s global platform coincides with a new supply partnership, as US taxi and e-fleet operator Curb Mobil

XPRIZE Announces the Two Winners of $20m NRG COSIA Carbon XPRIZE, With Each Team Creating Valuable Products out of CO2 Emissions19.4.2021 16:00:00 EEST | Press release

XPRIZE, the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges, today announced that CarbonCure Technologies and CarbonBuilt have won the $20M NRG COSIA Carbon XPRIZE, a prize that set out to convert CO2 emissions into valuable products. Selected by a panel of independent judges, both winning teams developed solutions aimed at reducing CO2 emissions associated with traditional concrete, which is currently the world’s most abundant human-made material and accounts for seven percent of all global CO2 emissions. The two team’s award-winning technologies will be, and already are, game-changers for global decarbonization and the fight against climate change. Launched in 2015, the NRG COSIA Carbon XPRIZE was a five-year global competition developed to address rising CO2 emissions by challenging innovators around the world to develop breakthrough technologies that convert the most CO2 into products with the highest net value. "Th

Duravant To Acquire Foodmate, Provider of Poultry Processing Solutions19.4.2021 16:00:00 EEST | Press release

Duravant LLC (“Duravant”), a global engineered equipment and automation solutions provider to the food processing, packaging and material handling sectors, announced today that it has entered into a definitive agreement to acquire Foodmate, a leading manufacturer of poultry processing equipment dual-headquartered in Ball Ground, Georgia, and Numansdorp, the Netherlands. Foodmate’s automated secondary processing solutions for poultry are widely recognized as the gold standard in the industry. “We are absolutely thrilled with this partnership,” said Mike Kachmer, President and CEO of Duravant. “Foodmate is the preferred provider of processing systems in the poultry processing industry globally. Combine that with their culture of laser-focused innovation and superior engineering expertise, Foodmate is a wonderful addition to the Duravant family.” This partnership brings together two global engineered equipment leaders and extends Duravant’s ability to serve customers and partners in over

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom